Cover Image

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Up to 20% of patients with multiple myeloma (MM) show signs of peripheral neuropathy (PN) at primary diagnosis.[1][1] Treatment with neurotoxic agents such as bortezomib or thalidomide increases rates of PN in newly diagnosed patients by up to 50%.[2][2] Since subcutaneous (SC) administration

Saved in:
Bibliographic Details
Main Authors: Merz, Maximilian (Author) , Mai, Elias K. (Author) , Bertsch, Uta (Author) , Hose, Dirk (Author) , Seckinger, Anja (Author) , Jauch, Anna (Author) , Hillengaß, Jens (Author) , Raab, Marc-Steffen (Author) , Schurich, Bärbel (Author) , Goldschmidt, Hartmut (Author)
Format: Article (Journal)
Language:English
Published: December 2016
In: Haematologica
Year: 2016, Volume: 101, Issue: 12, Pages: e485-e487
ISSN:1592-8721
DOI:10.3324/haematol.2016.151266
Online Access:Verlag, Volltext: http://dx.doi.org/10.3324/haematol.2016.151266
Verlag, Volltext: http://www.haematologica.org/content/101/12/e485
Get full text
Author Notes:Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Peter Brossart, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt
Description
Summary:Up to 20% of patients with multiple myeloma (MM) show signs of peripheral neuropathy (PN) at primary diagnosis.[1][1] Treatment with neurotoxic agents such as bortezomib or thalidomide increases rates of PN in newly diagnosed patients by up to 50%.[2][2] Since subcutaneous (SC) administration
Item Description:Gesehen am 26.09.2017
Physical Description:Online Resource
ISSN:1592-8721
DOI:10.3324/haematol.2016.151266

Similar Items